IFP Advisors’s Lisata Therapeutics LSTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-10
Closed -$21 3216
2023
Q3
$21 Buy
+10
New +$28 ﹤0.01% 3259
2023
Q1
Sell
-7
Closed -$2K 3999
2022
Q4
$2K Sell
7
-114
-94% -$418 ﹤0.01% 4179
2022
Q3
$2K Buy
121
+116
+2,320% +$841 ﹤0.01% 4374
2022
Q2
$1K Hold
5
﹤0.01% 4378
2022
Q1
$1K Hold
5
﹤0.01% 4377
2021
Q4
$1K Hold
5
﹤0.01% 3047
2021
Q3
$1K Hold
5
﹤0.01% 3059
2021
Q2
$0 Hold
5
﹤0.01% 3151
2021
Q1
$0 Hold
5
﹤0.01% 3135
2020
Q4
$0 Hold
5
﹤0.01% 3031
2020
Q3
$0 Hold
5
﹤0.01% 2938
2020
Q2
$0 Hold
5
﹤0.01% 2856
2020
Q1
$0 Hold
5
﹤0.01% 2893
2019
Q4
$0 Hold
5
﹤0.01% 3007
2019
Q3
$0 Buy
+5
New +$194 ﹤0.01% 3110
2019
Q1
$0 Hold
2
﹤0.01% 2959
2018
Q4
$0 Sell
2
-36
-95% -$2.5K ﹤0.01% 3726
2018
Q3
$3K Hold
38
﹤0.01% 3426
2018
Q2
$4K Hold
38
﹤0.01% 3369
2018
Q1
$2K Hold
38
﹤0.01% 3508
2017
Q4
$2K Hold
38
﹤0.01% 3559
2017
Q3
$2K Hold
38
﹤0.01% 3754
2017
Q2
$3K Hold
38
﹤0.01% 3625
2017
Q1
$3K Hold
38
﹤0.01% 3536
2016
Q4
$2K Buy
38
+33
+660% +$1.9K ﹤0.01% 3646
2016
Q3
$0 Hold
5
﹤0.01% 3974
2016
Q2
$0 Buy
+5
New +$460 ﹤0.01% 3965
2016
Q1
Sell
-5
Closed -$491 2954
2015
Q4
$1K Buy
+5
New +$918 ﹤0.01% 3534

Other funds holding LSTA

IFP Advisors's LSTA Position: Q4 2023 in Review

IFP Advisors sold out of Lisata Therapeutics (LSTA) in Q4 2023, closing a stake of 10 shares — an estimated $21 sold.

IFP Advisors first reported a position in LSTA in Q4 2015 and held it in 28 quarters. The position peaked at $4K in Q2 2018. 22 funds tracked by Wall St. Rank hold LSTA as of Q4 2023.

  • IFP Advisors reported no remaining Lisata Therapeutics position as of Q4 2023 after selling out during the quarter.
  • IFP Advisors sold 10 Lisata Therapeutics shares in Q4 2023, an estimated $21.
  • IFP Advisors first reported a position in Lisata Therapeutics in Q4 2015 and held it in 28 quarters.
  • IFP Advisors's Lisata Therapeutics position peaked at $4K in Q2 2018.
  • 22 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q4 2023.

Based on IFP Advisors's 13F filing for Q4 2023, filed 9 Jan 2024.